The Mortality in Emergency Department Sepsis (MEDS) score is a previously derived, validated, and published clinical decision rule for predicting 28-day inhospital mortality. It is based on the following scoring system: underlying disease with expected fatality \< 30 days or metastatic cancer (six points), tachypnea or hypoxia (three points), septic shock (three points), platelets \< 150,000 (three points), bands \> 5% (two points), age \> 65 years (two points), lower respiratory infection (two points), nursing home resident (two points), anion gap, and altered mental status (two points). The points are added and a risk group assigned.

Objective
=========

The objective of this study was to assess the ability of the MEDS score to predict 1-year mortality.

Methods
=======

A prospective observational, cohort study of consecutive emergency department (ED) patients seen at an urban university hospital with 50,000 annual ED visits. The study period was1 February 2000--1 February 2001. All patients, aged 18 years or older, at risk for infection as indicated by the ED physician ordering a blood culture were included. The MEDS score divides patients into very low risk (0--4 points), low risk (5--7 points), moderate risk (8--12 points), high risk (13--15 points), and very high risk (\> 15 points). The raw survival figures are reported with 95% confidence intervals (CIs) and compared with each other using Tukey\'s Test for pair-wise comparisons.

Results
=======

Of 3926 patient visits eligible for the study, 3763 (96%) were included. The overall 1-year mortality was 24% (95% CI: 22.7--25.4%) (904/3763). The 1-year mortalities for the groups were: very low risk 8.6% (0.08--1.2%), low 23% (1.0--3.5%), moderate 40% (5.8--10%), high 68% (11--24%), and very high 79% (37--66%), with all groups being statistically different from each other by Tukey\'s Test for pair-wise comparisons.

Conclusions
===========

The MEDS score is a good predictor of 1-year mortality in patients presenting to the ED with sepsis. Independent multicenter validation is needed prior to widespread application of this rule to test its performance in other patient populations.
